OptiBiotix Signs Major Supply Agreement for its Microbiome Modulating Cholesterol-Reduction Probiotic

d6d4fdd0-bcf5-4480-8f73-4ee148db27dbarticleimage.jpg

19 Jun 2017 --- Life sciences company OptiBiotix has signed a three-year supply agreement with HLH BioPharma Vertriebs GmbH for its cholesterol-reducing LPLDL probiotic supplement. Research into the LPLDL probiotic, presented at Vitafoods Europe in May 2017, demonstrated that it is a safe natural ingredient which reduces blood pressure and cholesterol, key determinates of cardiovascular risk. 

According to the company, the probiotic was found to reduce LDL cholesterol by up to 13.9%, and blood pressure by 5.1%. This research was carried out by Glenn Gibson, Professor of Food Microbiology, Head of Food Microbial Sciences at University of Reading.

Stephen O’Hara, CEO of OptiBiotix, comments, “The development of our LPLDL probiotic product has made cholesterol reduction through microbiome modulation a reality, and we are thrilled to be working with HLH, one of Europe’s leading suppliers to the pharmacy market, on this product. The ability to create designer active ingredients which can modify an individual’s microbiome to improve health places OptiBiotix at the forefront of global microbiome research and product development, and we anticipate many more opportunities for the LPLDL probiotic.”

Microbiome modulators in the form of probiotic supplements, like LPLDL, may be the way forward for managing long-term conditions like cardiovascular disease (CVD). The reduction of both LDL cholesterol and blood pressure is key for managing the risk of CVD. The combination of high blood pressure and cholesterol deposition may lead to the chronic inflammation and hardening of the walls of the blood vessels, which greatly increases the probability of suffering a cardiovascular event. Recent research, presented at the European Society of Cardiology Congress 2016, demonstrated that reducing LDL cholesterol and blood pressure can reduce the lifetime risk of cardiovascular disease by nearly 90%.

The supply agreement grants HLH a non-exclusive license to produce, package, and commercialize products containing the LPLDL strain, and follows HLH’s recent order for 100,000 units of LPLDL. HLH has over 20 years’ experience in the distribution of probiotic and natural products under the brand names Lactobact and Casa Sana and is one of Europe’s leading suppliers of probiotics to the pharmacy market. LPLDL will be supplied as bulk capsules which will be packaged and branded as part of HLH’s market leading Lactobact brand.

Related Articles

Nutrition & Health News

AI: Nuritas explores potential health benefits during Future of Nutrition Summit

13 Dec 2017 --- Biotechnology company Nuritas has innovative plans for using artificial intelligence (AI) to relieve the potential burden of future global health issues. These plans were outlined during its Future of Nutrition Summit held the day before FiE 2017 in Frankfurt, during which Nuritas Commercial Manager Neil Foster outlined the company’s use of AI for data mining for bioactive peptides, specific molecules with “tremendous” health benefits.

Business News

Vitafoods Europe to examine mainstreaming of personalized nutrition

13 Dec 2017 --- One of the major issues to be discussed at Vitafoods Europe 2018 will be how personalized nutrition can break out of its niche and achieve mass market appeal, the organizers of the global nutraceutical event have announced. Advances in genomics and wearable technology have created new opportunities for products tailored to individual consumers. And in a new poll conducted by the organizers, personalized nutrition ranks as one of the most important industry trends for 2018, behind only clean label and scientifically supported health claims.

Business News

Frutarom finalizes AB-Fortis micro-encapsulation technology acquisition

13 Dec 2017 --- Frutarom has acquired AB-Fortis activities, including a patent-protected micro-encapsulation technology that enables delivery of iron with increased biological absorption. Frutarom announced the signing of an agreement with AB-Biotics S.A. of Spain for the acquisition of the activity of AB-Fortis in November.

Business News

Kappa Bioscience moves to expand vitamin K2 presence in US with new appointments

13 Dec 2017 --- Kappa Bioscience AS, maker of K2Vital vitamin K2 MK-7, has appointed Garnet Pigden and New Jersey-based D2C to head-up the continued development of Kappa’s position in the US market. The appointment spans the establishment of strategy, infrastructure, partnerships and key accounts in support of an overall objective of solidifying vitamin K2 in mainstream US markets and channels, according to Kappa.

Nutrition & Health News

Researchers create app to predict and intervene in users' overeating

13 Dec 2017 --- Researchers at Worcester Polytechnic Institute (WPI) and the University of Connecticut (UConn) are collaborating on a smartphone app aimed at helping users manage their overeating challenges in three key ways: by tracking eating patterns, providing interventions and helping change behavior. According to the researchers, the app and its distinctive methodology have shown “tremendous promise” in an early pilot study.

More Articles
URL : http://www.nutritioninsight.com:80/news/optibiotix-signs-major-supply-agreement-for-its-microbiome-modulating-cholesterol-reduction-probiotic.html